Clinical Trial Update: To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on GS1191-0445 Injection to evaluate its safety and efficacy in hemophilia A (Phase 1/Phase 2; status not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• GS1191-0445 Injection

Snippet

Sponsor: Gritgen Therapeutics Co., Ltd. | Conditions: Severe Hemophilia A | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING